Which medications are metabolized by CYP2D6, and what are the strong inhibitors and inducers of this enzyme?

Medical Advisory BoardAll articles are reviewed for accuracy by our Medical Advisory Board
Educational purpose only • Exercise caution as content is pending human review
Article Review Status
Submitted
Under Review
Approved

Last updated: April 10, 2026 • View editorial policy

Have a follow-up question?

Our Medical A.I. is used by practicing medical doctors at top research institutions around the world. Ask any follow up question and get world-class guideline-backed answers instantly.

CYP2D6 Substrates, Inhibitors, and Inducers

CYP2D6 metabolizes approximately 25% of clinically used drugs (>100 medications), despite accounting for less than 2% of total hepatic cytochrome P450 enzymes 1.

Major CYP2D6 Substrates

Antidepressants

  • SSRIs: Fluoxetine, paroxetine, fluvoxamine, sertraline 23
  • SNRIs: Venlafaxine, desvenlafaxine, duloxetine 3
  • Tricyclics: Desipramine, imipramine, nortriptyline 24
  • Others: Atomoxetine 56

Antipsychotics

  • Aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone, zuclopenthixol 7
  • Clozapine, flupentixol, olanzapine (also metabolized by CYP2D6 but no dose adjustments recommended) 7

Cardiovascular Medications

  • Beta-blockers: Metoprolol 6
  • Antiarrhythmics: Flecainide 4

Analgesics

  • Codeine, tramadol 5

Other Notable Substrates

  • Dextromethorphan, debrisoquine, bufuralol 5

Strong CYP2D6 Inhibitors

Rank order of inhibitory potency (in vitro to in vivo correlation): Paroxetine > Fluoxetine ≈ Norfluoxetine > Sertraline ≥ Fluvoxamine 4

Clinical Effects of Strong Inhibitors:

  • Paroxetine: Produces approximately 3-fold increase in desipramine plasma concentrations at steady state 4
  • Fluoxetine (20 mg/day): Produces approximately 4-fold elevation in peak desipramine concentrations; inhibition persists for approximately 3 weeks after discontinuation due to long half-life of active metabolite norfluoxetine 48
  • Quinidine: Listed as strong inhibitor 5

The mechanism of fluoxetine's prolonged CYP2D6 inhibition is primarily competitive inhibition due to strong affinity binding and long elimination half-life of both fluoxetine and norfluoxetine, allowing unbound drug to circulate for extended periods 8.

Moderate CYP2D6 Inhibitors:

  • Sertraline (50 mg/day): Produces modest approximately 30% elevation in desipramine concentrations 4
  • Duloxetine 3
  • Cimetidine 9

Weak CYP2D6 Inhibitors:

  • Venlafaxine 4
  • Desvenlafaxine 9

Other Inhibitors Identified:

  • Cocaine, imipramine, thioridazine 5

CYP2D6 Inducers

CYP2D6 is largely uninducible by prototypical CYP inducers such as phenobarbital, rifampin, and dexamethasone 1. The enzyme is regulated by hepatocyte nuclear factor-4alpha rather than traditional induction mechanisms 1.

Clinical Implications by Metabolizer Phenotype

Poor Metabolizers (PMs):

  • Dose reductions recommended for: Aripiprazole, brexpiprazole, haloperidol, pimozide, risperidone, zuclopenthixol 7
  • Risk: Elevated drug levels leading to increased toxicity with fluoxetine, paroxetine, and venlafaxine 2

Intermediate Metabolizers (IMs):

  • Dose reductions recommended for: Pimozide and zuclopenthixol 7

Ultrarapid Metabolizers (UMs):

  • Dose increase or alternative drug recommended for: Haloperidol 7
  • Alternative drug or dose titration for: Risperidone 7
  • Consider dose increase if no clinical effect: Zuclopenthixol 7

Important Caveats

A critical finding is that 62% of FDA-listed moderate and weak inhibitors matched their classification when evaluated against primary literature, suggesting potential discordance in some classifications 9. The FDA classifications should be interpreted with clinical judgment, particularly for cimetidine, desvenlafaxine, and fluvoxamine where modifications have been suggested 9.

Drug-drug-gene interactions (DDGIs) are particularly complex with CYP2D6 due to high prevalence of genetic variation and common use of CYP2D6 inhibiting drugs 6. When multiple CYP2D6 substrates and inhibitors are combined, consider using PBPK modeling networks or consultation with clinical pharmacology for dose optimization 6.

Related Questions

In an intermediate CYP2D6 metabolizer, is fluvoxamine (Luvox) a better choice than fluoxetine (Prozac) when combined with aripiprazole (Abilify)?
What are the clinical implications and recommended drug dosing adjustments for patients who are genetically fast (ultra‑rapid) metabolizers of enzymes such as CYP2D6, CYP1A2, CYP3A5, NAT2, or UDP‑glucuronosyltransferases?
How does fluoxetine affect CYP2D6 metabolism and what precautions should be taken when prescribing CYP2D6 substrate drugs?
Can Wellbutrin (bupropion) be co‑prescribed with Paxil (paroxetine) in an adult patient without a history of seizures, eating disorders, or other contraindications and who is not taking strong CYP2D6‑inhibiting drugs?
Which stimulant medications are safest to use in patients who are taking CYP2D6 inhibitors?
In a patient with atrial fibrillation, a pacemaker, and on metoprolol (and gabapentin), does increasing the cyclobenzaprine dose increase the risk of adverse effects such as anticholinergic symptoms, excessive sedation, or cardiac complications?
After hip fracture repair, should I restart apixaban (Eliquis) or initiate enoxaparin (Lovenox) for venous thromboembolism prophylaxis?
What are the recommended dosing regimens, monitoring parameters, and precautions for prazosin in adults with hypertension, PTSD‑related nightmares, and benign prostatic hyperplasia?
Can changing Cymbalta (duloxetine) from a morning to an evening dose cause prolonged sedation rather than the THC exposure?
What is the appropriate management for a rash that develops after a single dose of amoxicillin?
What is metabolic‑dysfunction‑associated steatotic liver disease (MSLD) and how is LiverPrime (silymarin, phosphatidylcholine, vitamin E, omega‑3 fatty acids) used to promote a healthy liver?

Professional Medical Disclaimer

This information is intended for healthcare professionals. Any medical decision-making should rely on clinical judgment and independently verified information. The content provided herein does not replace professional discretion and should be considered supplementary to established clinical guidelines. Healthcare providers should verify all information against primary literature and current practice standards before application in patient care. Dr.Oracle assumes no liability for clinical decisions based on this content.